RP Bio (A314140) Stock Overview
A bio-health company, engages in the research, development, manufacture, and sale of soft capsules in Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A314140 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
RP Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,760.00 |
| 52 Week High | ₩9,130.00 |
| 52 Week Low | ₩5,400.00 |
| Beta | 0.52 |
| 1 Month Change | -7.84% |
| 3 Month Change | -19.67% |
| 1 Year Change | -1.71% |
| 3 Year Change | -49.74% |
| 5 Year Change | n/a |
| Change since IPO | -68.52% |
Recent News & Updates
Is RP Bio (KOSDAQ:314140) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is RP Bio (KOSDAQ:314140) A Risky Investment?
KOSDAQ:A314140 1 Year Share Price vs Fair Value Explore RP Bio's Fair Values from the Community and select yours Some...Recent updates
Shareholder Returns
| A314140 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -4.0% | -4.7% | 6.7% |
| 1Y | -1.7% | 17.3% | 195.0% |
Return vs Industry: A314140 underperformed the KR Pharmaceuticals industry which returned 17.3% over the past year.
Return vs Market: A314140 underperformed the KR Market which returned 195% over the past year.
Price Volatility
| A314140 volatility | |
|---|---|
| A314140 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in KR Market | 16.6% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A314140 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A314140's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | n/a | Jae-Hoon Yoon | www.rpbio.co.kr |
RP Bio Inc., a bio-health company, engages in the research, development, manufacture, and sale of soft capsules in Korea and internationally. It offers animal, vegetable, antihistamine, and chewable soft capsules; hard capsules; and jelly and powder sticks; Urusa, flagship soft capsule; omega-3 and lutein products, and granule, effervescent granule, and stick type capsule powders. The company also provides cold and liver medicines; vitamins; blood circulation improvers; and pain relievers.
RP Bio Inc. Fundamentals Summary
| A314140 fundamental statistics | |
|---|---|
| Market cap | ₩49.92b |
| Earnings (TTM) | ₩5.60b |
| Revenue (TTM) | ₩137.35b |
Is A314140 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A314140 income statement (TTM) | |
|---|---|
| Revenue | ₩137.35b |
| Cost of Revenue | ₩123.01b |
| Gross Profit | ₩14.35b |
| Other Expenses | ₩8.74b |
| Earnings | ₩5.60b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 646.49 |
| Gross Margin | 10.44% |
| Net Profit Margin | 4.08% |
| Debt/Equity Ratio | 17.6% |
How did A314140 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/30 22:25 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RP Bio Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.